Merck Beats on Both Top and Bottom Lines
Merck (NYS: MRK) reported earnings on July 27. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Merck beat slightly on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly and GAAP earnings per share contracted.
Gross margins increased, operating margins expanded, and net margins dropped.
Merck logged revenue of $12.31 billion. The 17 analysts polled by S&P Capital IQ foresaw revenue of $12.15 billion on the same basis. GAAP reported sales were 1.3% higher than the prior-year quarter's $12.15 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.05. The 19 earnings estimates compiled by S&P Capital IQ predicted $1.02 per share. GAAP EPS of $0.58 for Q2 were 11% lower than the prior-year quarter's $0.65 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 67.3%, 70 basis points better than the prior-year quarter. Operating margin was 24.3%, 150 basis points better than the prior-year quarter. Net margin was 14.6%, 210 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $11.72 billion. On the bottom line, the average EPS estimate is $0.94.
Next year's average estimate for revenue is $47.18 billion. The average EPS estimate is $3.82.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 2,695 members out of 2,903 rating the stock outperform, and 208 members rating it underperform. Among 763 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 723 give Merck a green thumbs-up, and 40 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Merck is outperform, with an average price target of $41.93.
- Add Merck to My Watchlist.
The article Merck Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.